ArticleJournal of inflammation research2025
ALDH2 Ameliorates Acute Gouty Arthritis Through Inhibiting NLRP3 Inflammasome and Pyroptosis by Nrf2/ROS Pathway.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gouty arthritis is a common disease characterized by the deposition of monosodium urate (MSU) crystals in joint and non-joint structures. Nonetheless, the role of aldehyde dehydrogenase 2 (ALDH2) in the pathophysiology of acute gout remains unclear. This study aimed to evaluate the role of ALDH2 in MSU crystal-induced acute gout attacks and related mechanisms and to identify potential therapeutic strategies for gout management. Methods: Peripheral blood mononuclear cells (PBMCs) from gout patients and healthy controls were isolated via Ficoll-Paque Plus density gradient centrifugation. A mouse model of gouty arthritis was established by injecting MSU crystal suspension into the foot pad. In vitro, PMA-differentiated THP-1 cells were stimulated with MSU crystals. We then investigated the effect of the ALDH2 agonist Alda-1 on MSU crystal-induced acute inflammation. Furthermore, the Nrf2 inhibitor ML385 was used to define the Nrf2 pathway's role in mediating ALDH2 activation effects during acute gout attacks. Results: We found that compared to healthy controls, ALDH2 expression was significantly decreased in the PBMCs of patients with acute gout and negatively correlated with C-reactive protein levels. In mice models with acute gout, treatment with Alda-1 effectively mitigated MSU-induced footpad edema, along with reductions in inflammatory cell infiltration and pro-inflammatory cytokine production in the local tissue of the footpad. In vitro studies demonstrated that Alda-1 significantly reduced oxidative stress induced by MSU crystal stimulation and suppressed the activation and assembly of the NLRP3 inflammasome, as well as the resulting pyroptosis. Further experiments revealed that Alda-1 treatment promoted Nrf2 nuclear translocation, alleviating oxidative stress and cellular inflammation. Conclusion: Our findings suggest that Alda-1-mediated activation of ALDH2 can alleviate MSU-induced oxidative stress and inflammation by regulating the Nrf2/ROS pathway and may represent a promising therapeutic strategy for managing acute gouty arthritis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.